180
Participants
Start Date
June 30, 2010
Primary Completion Date
March 31, 2013
Study Completion Date
March 31, 2018
Entecavir
Tablets/oral solution, 0.015 mg/kg up to 0.5 mg, administered orally, once daily, for 96 to144 weeks, depending on response
Placebo
Tablets/oral solution, 0 mg, administered orally, once daily, for 48 to 96 weeks, depending on response
Local Institution, Taipei
Local Institution, Tainan City
Local Institution, Brussels
Local Institution, Bunos Aires
Mount Sinai Medical Center, New York
Local Institution, Safed
Children'S Hospital Of Philadelphia, Philadelphia
Children'S National Medical Center, Washington D.C.
Johns Hopkins School Of Medicine, Baltimore
Inova Fairfax Hospital For Children, Fairfax
Levine Children'S Hospital At Carolinas Medical Center, Charlotte
Romero, Rene, Atlanta
University Of Florida, Gainesville
Local Institution, Wuppertal
Indiana University School Of Medicine / Riley Hospital, Indianapolis
Local Institution, Thesaloniki
Local Institution, Mainz
Texas Children'S Hospital, Houston
Local Institution, Starnberg
Local Institution, Beersheba
University Of California, San Francisco, San Francisco
Local Institution, Moscow
Local Institution, Moscow
Local Institution, Saint Petersburg
Local Institution, Timișoara
Local Institution, Hyderabad
Local Institution, Novokuznetsk
Local Institution, Iași
Local Institution, Guwahati
Connecticut Children'S Medical Center, Hartford
Shah, Uzma, Boston
Boston Childrens Hospital, Boston
Rhode Island Hospital, Providence
Local Institution, Toronto
Local Institution, Petah Tikva
Local Institution, Bydgoszcz
Local Institution, Krakow
Local Institution, Wroclaw
Local Institution, Bucharest
Local Institution, Daegu
Local Institution, Seoul
Local Institution, Seoul
Local Institution, London
Local Institution, Birmingham
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY